| 6.67 0.17 (2.62%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.64 | 1-year : | 9.41 |
| Resists | First : | 7.39 | Second : | 8.06 |
| Pivot price | 6.76 |
|||
| Supports | First : | 6.32 | Second : | 5.26 |
| MAs | MA(5) : | 6.8  |
MA(20) : | 6.86 |
| MA(100) : | 5.13 |
MA(250) : | 4.01 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 24 |
D(3) : | 29.9 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 8.06 | Low : | 1.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MASS ] has closed above bottom band by 39.8%. Bollinger Bands are 49.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.7 - 6.74 | 6.74 - 6.78 |
| Low: | 6.29 - 6.33 | 6.33 - 6.38 |
| Close: | 6.6 - 6.67 | 6.67 - 6.73 |
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Wed, 16 Jul 2025
Favourable Signals For 908 Devices: Numerous Insiders Acquired Stock - Yahoo
Wed, 09 Jul 2025
When Every Second Counts: This UNC Device is Saving Lives - UNC News
Tue, 08 Jul 2025
908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances - Business Wire
Thu, 26 Jun 2025
908 Devices (MASS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Mon, 16 Jun 2025
908 Devices Appoints Christopher D. Brown To Board - citybiz
Wed, 14 May 2025
908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 36 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 8.4 (%) |
| Held by Institutions | 73.9 (%) |
| Shares Short | 2,330 (K) |
| Shares Short P.Month | 2,610 (K) |
| EPS | -2.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.46 |
| Profit Margin | -27.7 % |
| Operating Margin | -72.5 % |
| Return on Assets (ttm) | -16.1 % |
| Return on Equity (ttm) | -48.2 % |
| Qtrly Rev. Growth | 58.7 % |
| Gross Profit (p.s.) | 0.88 |
| Sales Per Share | 1.78 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -3.01 |
| PEG Ratio | 0 |
| Price to Book value | 1.49 |
| Price to Sales | 3.73 |
| Price to Cash Flow | -6.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|